(Q47815070)

5 February 2018

title

The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab (English)

1 reference

5 February 2018

1 reference

1 reference

Mira Lim

1

1 reference

5 February 2018

Deborah S Jacobs

series ordinal

2

1 reference

5 February 2018

Perry Rosenthal

series ordinal

3

1 reference

5 February 2018

Karen G Carrasquillo

series ordinal

4

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 May 2009

1 reference

5 February 2018

Seminars in Ophthalmology

published in

1 reference

5 February 2018

volume

24

1 reference

5 February 2018

issue

3

1 reference

5 February 2018

page(s)

149-155

1 reference

5 February 2018

Corneal neovascularization

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

21 January 2018

Update on scleral lenses

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Gas-permeable scleral contact lens therapy in ocular surface disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530902802013

10.1080/08820530902802013

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018